

FORM-PTO-1390
(Rev. 10-96)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

015200-054

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)

09/011,977

INTERNATIONAL APPLICATION NO.
PCT/EP96/03705

INTERNATIONAL FILING DATE
22 August 1996

PRIORITY DATE CLAIMED
23 August 1995

TITLE OF INVENTION
USE OF BOSWELLIC ACID AND ITS DERIVATIVES FOR INHIBITING NORMAL AND INCREASED
LEUCOCYTIC ELASTASE OR PLASMIN ACTIVITY

APPLICANT(S) FOR DO/EO/US
Hermann P.T. AMMON; Hasan SAFAYHI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

06/17/1998 PVOLPE 00000020 09011977

01 FC:154

130.00 DP

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.50)
09/011,977

INTERNATIONAL APPLICATION NO.
PCT/EP96/03705

ATTORNEY'S DOCKET NUMBER
015200-054

17. ☒ The following fees are submitted:

CALCULATIONS

PTO USE ONLY

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO \$930

International preliminary examination fee paid to USPTO (37 CFR 1.482) \$720.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482) \$790.00

but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$1070.00

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1070.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$98.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130.00

Claims

Number Filed

Number Extra

Rate

Total Claims -20 =

X\$22.00

\$

Independent Claims -3 =

X\$82.00

\$

Multiple dependent claim(s) (if applicable)

+ \$270.00

\$

TOTAL OF ABOVE CALCULATIONS =

\$ 130.00

Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$ 130.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 130.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$ 40.00

TOTAL FEES ENCLOSED =

\$ 170.00

Amount to be:
refunded \$

charged \$

a. ☒ A check in the amount of \$ 170.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Norman H. Stepno
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

SIGNATURE

Teresa Stanek Rea
NAME

30,427

REGISTRATION NUMBER

28 Rec'd PCT/PTO 20 FEB 1998

09/011977

Patent
Attorney's Docket No. 015200-054

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Hermann AMMON et al)
Application No.: Unassigned) Group Art Unit: Unassigned
(Corresponds to PCT/EP96/03705))
International Filing)
Date: 22 August 1996) Examiner: Unassigned
For: USE OF BOSWELLIC ACID AND)
ITS DERIVATIVES FOR)
INHIBITING NORMAL AND)
INCREASED LEUCOCYTIC)
ELASTASE OR PLASMIN ACTIVITY)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-captioned application as follows:

IN THE CLAIMS:

Kindly cancel claims 1-9 without prejudice or disclaimer.

Kindly add new claims 10-16 as follows:

--10. A method for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, said method comprising administering an effective amount of boswellic acid, a physiologically acceptable salt, a derivative, a salt of

the derivative or a plant preparation containing boswellic acid to prevent and/or combat said diseases to a mammalian organism in need of such prevention and/or combatting.

--11. The method as claimed in claim 10, wherein said disease is pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis or rheumatoid arthritis, which are caused by increased leucocytic elastase activity, or tumors and neoplasm or tumor metastases which are caused by increased plasmin activity.

--12. The method as claimed in Claim 10, wherein said boswellic acid is administered intraperitoneally, orally, buccally, rectally, intramuscularly, topically, subcutaneously, intraarticularly, intravenously or inhalationally.

--13. The method as claimed in claim 10, wherein said boswellic acid is administered in the form of tablets, dragees, capsules, solutions, emulsions, ointments, creams, inhalants, aerosols or suppositories.

--14. The method as claimed in Claim 10, wherein said mammalian organism is an animal.

--15. The method as claimed in Claim 10, wherein said mammalian organism is a human.

--16. The method as claimed in Claim 10, wherein a chemically pure medicinal or plant substance is also present.--

REMARKS

Entry of the foregoing Amendment is respectfully requested.

The claims have been amended to eliminate multiple dependency and to place them in better condition for U.S. patent practice.

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: February 20, 1998

20 FEB 1998

09/011977

Description

Use of boswellic acid and its derivatives for inhibiting
normal and increased leucocytic elastase or plasmin
activity

The invention concerns the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.

The invention further concerns the use of pure boswellic acid or a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preparing a medicament for treating diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.

According to the invention, use is made thereof particularly in the case of pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, which are caused by increased leucocytic elastase activity, tumors and neoplasm or tumor metastases, which are caused by increased plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity.

09011977 "09011977"

inactivated form in neutrophilic granulocytes (PMNL) of humans, released from granules of these cells upon activation of the neutrophilic granulocytes and, as enzyme (serine protease), it then catalyzes the proteolytic degradation of elastin, collagen, fibronectin and further proteins.

Pathophysiological significance

Together with other inflammatory mediators, the serine protease activity of human leucocytic elastase takes part in the formation and maintenance of pathologic changes and the aggravation of such processes - particularly due to the degradation of components of the framework of many organs and tissues. In so far, human leucocytic elastase is attributed to play a part in the following diseases of humans (for a survey: cf. Janoff, Annu. Rev. Med. 36: 207-216, 1985):

- pulmonary emphysema, acute respiratory distress syndrome, shock lung,
- cystic fibrosis (mucoviscidosis),
- chronic bronchitis,
- glomerulonephritis,
- rheumatoid arthritis.

In general, participation of human leucocytic elastase is postulated in catabolic processes of inflammations of various genesis, which are accompanied by neutrophilic granulocyte infiltration. From basic findings obtained in connection with isolated cells, it can be concluded that it plays a part in the endotoxin-triggered hepatic damage conveyed by

conveyed by neutrophilic granulocytes (Sauer et al., Naunyn-S. Arch. Pharmacol. 351 S: Abstract. 495, 1995).

Inhibitors of human leucocytic elastase

A plurality of naturally occurring and synthetic inhibitors for human leucocytic elastase are known (Groutas 1987, Med. Res. Rev. 7: 227-241; Bode et al. 1989, Biochemistry 28: 1951-1963). The effectiveness of some of these compounds is shown in experimental animal models (Powers 1983, Am. Rev. Respir. Dis. 127: p. 54 - p. 58; Schnebli 1985, in Handbook of Inflammation, Eds: Bonta, Bray & Parnham, Vol. 5: 321-333, Elsevier Sci. Publ., Amsterdam; Soskel et al. 1986, Am. Rev. Respir. Dis. 133: 635-638). The inhibition of human leucocytic elastase by some pentacyclic triterpene derivatives was shown. In this connection, the effectiveness of the individual derivatives was different (K_i values 4 to 185 μM). Ursolic acid ($K_i = 4$ to 6 μM) was the most effective one. The boswellic acid series was not tested in this study (Ying et al. 1991, Biochem. J. 277: 521-526).

Method of measuring human leucocytic elastase activity *in vitro*

The activity was determined photometrically with pure human leucocytic elastase (Calbiochem) and the substrate MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide in Dulbecco's phosphate-buffered salt solution (DPBS) in the presence of 10 % dimethyl sulfoxide (DMSO) at room temperature and 405 nm (Bieth et al. 1974, Biochem. Meth. 11: 350-357).

Method of measuring the chymotrypsin (CT) activity *in vitro*

The effect which acetyl-11-keto- β -boswellic acid (AKBA) has on the pure chymotrypsin activity (Sigma) was also determined to investigate a possible non-selective inhibition of various serine proteases. The test was carried out photometrically with MeO-Suc-Ala-Ala-Pro-Phe-p-

001197.001197

nitroanilide as a substrate in Dulbecco's phosphate-buffered salt solution (DPBS) in the presence of 10 % dimethyl sulfoxide at room temperature and 410 nm.

Results of the inhibition of leucocytic elastase activity by boswellic acids

In an established *in vitro* test system, the activities of two serine protease enzymes (human leucocytic elastase and chymotrypsin) were measured. Pure enzymes from Calbiochem and SIGMA, respectively, were used, and the enzyme activity was determined as the rate at which the enzymes released p-nitroaniline from their substrates by hydrolysis per time unit. Three series of measurement were made for determining the HLE activity at three different substrate concentrations. The 100 % controls did not contain any test substances but only the corresponding amount of solvent. The effects which differing concentrations of acetyl-11-keto- β -boswellic acid (AKBA) had on the human leucocytic elastase in these three series of measurement are shown as percentage of 100 % controls as mean values \pm S.D. of three independent measurements each.

1. Acetyl-11-keto- β -boswellic acid inhibited human leucocytic elastase in a concentration-depending manner with IC₅₀ values of about 17 μ M (at substrate concentrations of 50, 100 and 150 μ M). In the case of 20 μ M of acetyl-11-keto- β -boswellic acid, a residual activity of 18 % remained; in the case of 20 μ M of ursolic acid, the residual activity was 11 % (cf. fig. 1).

2. At a concentration of 20 μ M each in the test, the following compounds used as reference substances had no inhibitory effect in this system: as pentacyclic triterpene derivative: glycerrhitinic acid, as reducing and/or competitive 5-lipoxygenase inhibitors: NDGA, MK886 and ICI230,487, as steroids: cortisol and testosterone, and as polyunsaturated long-chain fatty acid: arachidonic acid.

3. Acetyl-11-keto- β -boswellic acid (AKBA) had no significant inhibitory effect on the chymotrypsin activity at concentrations of 50 and 100 μ M (89 and 85 of the control activity), whereas ursolic acid inhibited the activity of chymotrypsin at 50 μ M to 56 % and at 100 μ M to 30 % of the control activity of chymotrypsin.

Summary of the results concerning the inhibition of human leucocytic elastase

It follows from these results that acetyl-11-keto- β -boswellic acid also has an inhibitory effect on human leucocytic elastase in addition to its 5-lipoxygenase-inhibiting property and the accompanying reduction of leucotriene biosynthesis.

The inhibition of this enzyme is of importance because during the pathophysiological processes of the above-mentioned diseases (pulmonary emphysema, acute respiratory distress syndrome, shock lung, chronic bronchitis, cystic fibrosis, glomerulonephritis and rheumatoid arthritis) the human leucocytic elastase released from the activated neutrophilic granulocytes plays an important part in the destruction of functional tissue and thus is responsible for the damage caused by these diseases in the lungs, kidneys and joints. Therefore, it should be possible to prevent the damage of the organs resulting from these diseases by the inhibition of human leucocytic elastase by boswellic acid or the derivatives thereof. Selective inhibitors of human leucocytic elastase have not been available up to the present. However, non-selective inhibitors are not suitable for pharmacotherapy, since they can cause serious undesired effects because they inhibit other proteases as well. Moreover, boswellic acids and derivatives are well resorbed and, as has been proved, not toxic. Another advantage occurring when boswellic acids are used consists in that the synchronous inhibition of two inflammation-promoting mediator systems of leucocytes could be utilized synergistically by this monosubstance for the

PLASMIN

Like human leucocytic elastase, plasmin (EC 3.4.21.7.) is a serine protease. As an enzyme plasmin catalyzes the hydrolysis of peptide bonds, in which arginine and lysine take part, and thus the degradation of a number of proteins and peptides. Plasmin occurs in the blood as the inactive precursor plasminogen, and is formed by proteolytic activation from the precursor (plasminogen). The increased activity of plasmin is held responsible for the destruction of cell framework proteins occurring in the course of many diseases, but also for the invasive growth and metastatic spread of malignant tumors, which is accompanied by the destruction of endogenous functional tissue (Wangh et al., Int. J. Cancer. 1994, 58: 650-657). Moreover, plasmin also activates what is called growth factors which can also stimulate the reproduction of tumors (Campbell et al., J. Cell. Physiol. 1994, 159: 1-10). Therefore, it appears to be possible to inhibit the growth and metastatic spread of many kinds of cancer by inhibition of the plasmin activity.

Inhibition of the plasmin activity by boswellic acids

Method: Measurement of the plasmin activity

The activity of human plasmin (SIGMA) was determined photometrically *in vitro* with the substrate D-Ile-Phe-Lys-pNA (Cs-Szabo et al., Thrombosis Res. 1980, 20: 199-206). The plasmin activity is referred to as the release of p-nitronaniline per minute (nmole/min) from the substrate as mean values \pm S.D. of $n = 3$ measurements each.

Results

The pentacyclic triterpenic acids from the boswellic acid series, β -boswellic acid (β -BA) and acetyl-11-keto- β -boswellic acid (AKBA), inhibit the plasmin activity with comparable effectiveness with half-maximum inhibition constants of about 4 to 6 μ M (fig. 2, Ills. 1 and 2). In contrast to the inhibition of HLE (human leucocytic elastase), ursolic acid is markedly less effective with respect to the effect on the plasmin activity (IC₅₀ of about 15 μ M; fig. 2, Ill. 3), whereas amyrin does not influence significantly the plasmin activity at concentrations up to 50 μ M (not shown).

Summary

In an *in vitro* test system, β -BA and AKBA inhibited almost completely the plasmin activity at concentrations which following oral administration of olibanum or frankincense extracts can be reached in the blood of humans. Other pentacyclic triterpenic acids are either substantially weaker (ursolic acid) or not effective at all (amyrin) in this system.

Since the plasmin activity represents one of the essential mechanisms of malignant tumor growth, which is accompanied by the destruction of functional tissue in the host organism, it appears to be likely that the formation of

Up to the present, no satisfactory method of treatment is available in the therapy of diseases such as pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, diseases which are caused by increased leucocytic elastase activity, and tumors and neoplasm or tumor metastases which are caused by increased plasmin activity.

In the case of an emphysema recombinant α 1-antitrypsin can be substituted when an α 1-antitrypsin deficiency (deficiency of endogenous protease inhibitor) is given. In the case of ARDS: Acute/Adult Respiratory Distress Syndrome (shock lung), an acutely life-threatening pulmonary dysfunction which proceeds like a shock and represents the most frequent cause of death in patients who survived the early stage of a shock resulting from a primarily non-pulmonary cause and is a dangerous complication occurring in traumatized and operated patients, aprotinin, corticoids, heparin and low-molecular dextrans are used as

medicaments. Depending on the duration of respiratory insufficiency, lethality is still 30 to 90 % these days.

Cystic fibrosis (mucoviscidosis) is a hereditary metabolic anomaly which due to a generalized dysfunction of exocrine glands (increased production and high viscosity of the secretion of the mucous glands of the bronchi and the digestive apparatus) leads to serious complications in the region of the respiratory apparatus and in the pancreas, which progressively result in the degradation of functional tissue in the affected organs. The treatment focuses predominantly on the prevention of complications by the continuous care of the respiratory apparatus (physiotherapy, inhalations, early and well-calculated antibiotics).


In the case of arthritis (inflammations of a joint), processes proceeding together with hydrolizing enzymes (e.g. leucocytic elastase) result in degenerative changes of the capsule. By way of medicament, the secondary pain or after-pain is prevented symptomatically using non-steroidal antirheumatics. Treatment of the causally responsible secondary damage occurring in connection with primary-inflammatory arthritis is possible by means of steroids (corticoids) but out of the question because of the serious undesired side-effects. A direct inhibition of catabolic processes proceeding along with leucocytic elastase is not possible these days. Glomerulonephritis is a general term for widely differing renal diseases accompanied by inflammatory processes which may result in degenerative processes including terminal renal failure. Causal treatment is lacking. In the case of some forms, corticoids may help, serious undesired effect having to be accepted.

For treating the above-mentioned diseases, the pharmaceutical industry is hectically searching for leucocytic elastase and plasmin inhibitors which are non-toxic.

Surprisingly it has now been found that boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid can be used for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity, in human or veterinary medicine.


The structural formulae of boswellic acid and some of their derivatives are listed below:

(A):



R	= H	:	11-keto- β -boswellic acid
R	= acetyl	:	acetyl-11-keto- β -boswellic acid
R	= formyl	:	formyl-11-keto- β -boswellic acid

(B):



R	= H	:	α -boswellic acid
R	= acetyl	:	acetyl- α -boswellic acid
R	= formyl	:	formyl- α -boswellic acid

β -boswellic acid is preferably used as boswellic acid. According to the literature, it is isolated from *Boswellia serrata* or other known plants containing boswellic acid. β -boswellic acid may contain minor amounts of α - or γ -boswellic acid. Sodium, potassium, ammonium, calcium salts can be used as physiologically acceptable salts of boswellic acid. Lower alkyl esters obtained by esterification of the carboxyl group with a C_1 - C_6 alcohol,

Boswellic acid is administered according to the invention as required. Since it shows little toxicity, its dosage is not critical and can easily be varied by the physician

depending on the severity of the disease, the weight of the patient to be treated and the duration of treatment.

Unit doses may be administered one to four times daily, for example. The accurate dose depends on the way of administration, the condition to be treated, the patient's weight, etc. By nature, it may be required to vary the dose as a matter of routine, depending on the age and weight of the patient as well as the severity of the condition to be treated.

The preparations used according to the invention can be formulated in known manner by using one or more pharmaceutically acceptable carriers or diluents. The preparations can be formulated for intraperitoneal, oral, buccal, parenteral, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous or intranasal administration or in a way suitable for administration by inhalation or insufflation. Preparations of the compounds for oral administration are preferred.

The pharmaceutical preparations can be made in the form of tablets, dragees, capsules, solutions, emulsions, ointments, creams, inhalants, aerosols or suppositories.

The pharmaceutical preparations for oral administration may be available in the form of tablets or capsules, for example, which are produced according to methods known per se with pharmaceutically acceptable diluents, such as binders (pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose, for example), fillers (e.g. lactose, saccharose, mannitol, corn starch, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. stearic acid, polyethylene glycol, magnesium stearate, talcum or silicon dioxide); disintegrating agents (e.g. potato starch, sodium starch glycolate or sodium carboxymethyl cellulose); or wetting agents (e.g. sodium lauryl sulfate). The tablets can be coated according to methods known per se. Liquid

090457, 064598

THE UNIVERSITY OF CHICAGO

pharmaceutically acceptable additives, such as suspending agents (e.g. sorbitol syrup, cellulose derivatives, glucose/sugar syrup, gelatin, aluminum stearate gel or hydrogenated edible fats); emulsifiers (for example, lecithin, gum arabic or sorbitan monooleate); non-aqueous carriers (e.g. almond oil, oily esters, ethyl alcohol or fractional plant oils); and preservatives (methyl or propyl-p-hydroxy-benzoates or sorbic acid, for example). The liquid preparations may also contain generally known buffers, flavoring agents, colorants and sweeteners, as required.

For the parenteral administration the compounds can be formulated for injection, preferably intravenous, intramuscular or subcutaneous injection. Preparations for injection may be available in the form of single doses, e.g. in ampoules, or multiple-dose containers with a preservative added. The preparations can be available in the form of suspensions, solutions or emulsions in oily or aqueous carriers and contain preparation aids, such as suspending agents, stabilizers and/or dispersants, and/or agents for adjusting the tonicity of the solution. As an alternative, the active ingredient may be available in the form of a powder for the constitution with a suitable carrier, e.g. sterile pyrogen-free water, prior to use.

The compounds may also be formulated as rectal preparations such as suppositories, e.g. those which contain generally known base materials for suppositories, such as cocoa butter or other glycerides.

For intranasal administration, the compounds can be used as liquid sprays, in the form of drops or as snuff powder.

For administration by inhalation, the compounds are usefully supplied in the form of an aerosol spray from a pressurized pack by using suitable propellants or from an atomizer. In the case of a pressurized aerosol, the unit dose is determined by providing a valve which releases a

090137 "061598

The following examples explain the use according to the invention.

Tablets for oral administration

(1)

The active substance is mixed with anhydrous lactose and the magnesium stearate, and the mixture is sieved. The resulting mixture is compressed into tablets by means of a tableting machine.

Active substance: boswellic acid	15 - 30 mg/tablet
(and powderized drug, respectively	0.5 - 1.0 g/tablet)
magnesium stearate BP	0.7 mg/tablet
microcrystalline cellulose NF	100 mg/tablet

The active substance is sieved and mixed with the microcrystalline cellulose and magnesium stearate. The resulting mixture is compressed into tablets by means of a tabletting machine.

B. Wet granulation

Active substance: boswellic acid	15 - 30 mg/tablet
(and powdered drug, respectively	0.5 - 1.0 g/tablet)
lactose BP	150.0 mg/tablet
starch BP	30.0 mg/tablet
pregelatinized corn starch BP	15.0 mg/tablet
magnesium stearate BP	1.5 mg/tablet

The active substance is sieved through a suitable screen and mixed with the lactose, starch and pregelatinized corn starch. Suitable volumes of purified water are added, and the powder is granulated. After drying, the granulate is sieved and mixed with the magnesium stearate. The granulate is then compressed into tablets by means of punches having a suitable diameter.

Tablets of differing composition can be produced by changing the ratio of active substance to lactose or the compression weight and using corresponding punches.

E x a m p l e 2

Capsules

Active substance: boswellic acid	15 - 30 mg/capsule
(and granulated drug, respectively	0.5 - 1.0 g/capsule)
free-flowing starch	150.00 mg/capsule
magnesium stearate BP	1.00 mg/capsule

The active substance is sieved and mixed with other components. The mixture is filled into hard gelatin capsules No. 2 by using a suitable apparatus. Other capsules can be produced by changing the input weight and, if necessary, by changing the capsule size correspondingly.

Example 3

Syrup

saccharose-free preparation		<u>mg/5 ml dose</u>
active substance: boswellic acid		15 - 30
hydroxypropyl methyl cellulose USP (viscosity type 4000)		22.5
buffer)	
flavoring agent)	
coloring matter)	as required
preservative)	
sweetener)	
purified water	to	5.0 ml

The hydroxypropyl methyl cellulose is dispersed in hot water, cooled down and then mixed with an aqueous suspension containing the active substance and the other components of the preparation. The resulting solution is adjusted to its volume and mixed.

Example 4

Suspension

<u>Suspension</u>	<u>mg/5 ml dose</u>
active substance: boswellic acid	15 - 30
(and powderized drug, respectively	0.5 - 1.0 g)
(dried drug extract correspondingly)	
aluminum monostearate	75.00
sweetener)	
flavoring agent)	as required
coloring matter)	
fractional coconut oil to	5.00

The aluminum monostearate is dispersed in about 90 % of the fractional coconut oil. The resulting suspension is heated to 115°C by stirring and then cooled down. The sweeteners, flavoring agents and coloring matters are added, and the active substance is dispersed. The suspension is adjusted with the rest of the fractional coconut oil to the volume and mixed.

E x a m p l e 5

Sublingual tablet

Active substance: boswellic acid	15 - 30 mg/tablet
(and drug extract, respectively	0.5 - 1.0 g/tablet)
moldable sugar NF	50.5 mg/tablet
magnesium stearate BP	0.5 mg/tablet

The active substance is sieved through a suitable screen, mixed with the other components and compressed by means of suitable punches. Tablets of differing strength can be produced by changing the ratio of active substance to carrier or the compression weight.

E x a m p l e 6

Suppositories for rectal administration

Active substance: boswellic acid	15 - 30 mg
Witepsol H15+ to	1.0 g
+ suitable quality of Adeps solidus Ph.Eur.	

A suspension of the active substance in molten Witepsol is produced and filled into 1-g suppository molds by means of a suitable device.

E x a m p l e 7

Injection for intravenous administration

Active substance: boswellic acid	15 - 30 mg/ml
sodium chloride-intravenous	
infusion BP	
0.9 % wt./vol. to	1 ml
<u>batch size</u> 2500 ml	

The active substance is dissolved in part of the sodium chloride-intravenous infusion, the solution is adjusted with the sodium chloride-intravenous infusion to the

Cartridge for inhalation

Active substance (micronized):	15 - 30 mg/cartridge
boswellic acid	
lactose BP	25.00

Example 9

Active substance: boswellic acid	1.5 - 3.0 %/vol.
preservative)	as required
sodium chloride BP)	
purified water BP to	100

The active substance, preservative and sodium chloride are dissolved in part of the water. The solution is adjusted with water to the volume, and the solution is thoroughly mixed.

Claims

1. Use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.
2. Use according to claim 1, characterized in that use is made in the case of pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, which are caused by increased leucocytic elastase activity, and in the case of tumors and neoplasm or tumor metastases which are caused by increased plasmin activity.
3. Use according to claim 1 or 2, characterized in that use is made intraperitoneally, orally, buccally, rectally, intramuscularly, topically, subcutaneously, intraarticularly, intravenously or inhalationally.
4. Use according to at least one of claims 1 to 3, characterized in that use is made in the form of tablets, dragees, capsules, solutions, emulsions, ointments, creams, inhalants, aerosols or suppositories.
5. Use of pure boswellic acid or a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for the preparation of a medicament for treating diseases which are caused by increased leucocytic elastase or plasmin activity or which can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.


7. Use according to claim 6, characterized in that use is made for the preparation of a medicament for the intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous or inhalational administration.

9. Use according to at least one of claims 1 to 8, characterized in that use is made together with other chemically pure medicinal substances, and/or plant medicaments.

• 1 1

The invention further concerns the use of pure boswellic acid or a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preparing a medicament for treating diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.

Fig. 1
Inhibition of HLE by AKBA



100% = 21nMol/s


III. 1

100% = 35nMol/s

III. 2

100% = 43nMol/s

III. 3



**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR UTILITY PATENT APPLICATION**

Attorney's Docket No.

015200-054

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

USE OF BOSWELLIC ACID AND ITS DERIVATIVES FOR INHIBITING NORMAL AND INCREASED

LEUCOCYTIC ELASTASE OR PLASMIN ACTIVITY

the specification of which

(check one)

☐

is attached hereto;

☒

was filed on 22 April 1996 as

International Application No. PCT/EP96/03705

and was amended on _____;
(if applicable)

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code Sec. 119 and/or Sec. 365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No.

015200-054

COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
Germany	195 31 067.5	23 August 1995	YES <u>X</u> NO <u> </u>
			YES <u> </u> NO <u> </u>

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Ralph L. Freeland, Jr.	16,110	William C. Rowland	30,888
Peter H. Smolka	15,913	Robert G. Mukai	28,531	T. Gene Dillahunt	25,423
Robert S. Swecker	19,885	George A. Hovanec, Jr.	28,223	Anthony W. Shaw	30,104
Platon N. Mandros	22,124	James A. LaBarre	28,632	Patrick C. Keane	32,858
Benton S. Duffett, Jr.	22,030	E. Joseph Gess	28,510	Bruce J. Boggs, Jr.	32,344
Joseph R. Magnone	24,239	R. Danny Huntington	27,903	William H. Benz	25,952
Norman H. Stepno	22,716	Eric H. Weisblatt	30,505	Peter K. Skiff	31,917
Ronald L. Grudziecki	24,970	James W. Peterson	26,057	Richard J. McGrath	29,195
Frederick G. Michaud, Jr.	26,003	Teresa Stanek Rea	30,427	Matthew L. Schneider	32,814
Alan E. Kopecki	25,813	Robert E. Krebs	25,885	Michael G. Savage	32,596
Regis E. Slutter	26,999	Robert M. Schulman	31,196	Gerald F. Swiss	30,113
Samuel C. Miller, III	27,360				

and:

Address all correspondence to:

Norman H. Stepno
Burns, Doane, Swecker & Mathis, LLP
P.O. Box 1404
Alexandria, Virginia 22313-1404

Address all telephone calls to: Norman H. Stepno at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR		SIGNATURE	DATE
Hermann P.T. AMMON		<i>[Signature]</i>	11/05/98
RESIDENCE		CITIZENSHIP	
Im Kleeacker 30, D-72072 Tubingen, Germany <i>DE-X</i>		Germany	
POST OFFICE ADDRESS			
Im Kleeacker 30, D-72072 Tubingen, Germany			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY		SIGNATURE	DATE
Hasan SAFAYHI		<i>[Signature]</i>	11/05/98
RESIDENCE		CITIZENSHIP	
Eichenweg 5, D-72076 Tubingen, Germany <i>DE-X</i>		Germany	
POST OFFICE ADDRESS			
Eichenweg 5, D-72076 Tubingen, Germany			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			